

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### Evaluation of the efficacy of colistin / levofloxacin in comparison with colistin / meropenem in the treatment of ventilator-associated pneumonia (VAP) induced by carbapenem-resistant *Acinetobacter baumannii*: a randomized, controlled clinical trial

#### Protocol summary

##### Study aim

1. Determining the number of treatments, clinical improvement and treatment failure (clinical response) in the experimental group after treatment  
2. Determining the number of treatments, clinical improvement and treatment failure (clinical response) in the control group after treatment  
3. Comparison 1 and 2  
4. Determining the number of cases of microbial eradication and microbial failure (microbiological response) in the experimental group after treatment  
5. Determining the number of other microbial cases and microbial failure (microbiological response) in the control group after treatment  
6. Compare 4 and 5  
7. Determining the index of clinical score of lung infection (clinical score of lung infection [CPIS]) in the experimental group before and after the intervention

##### Design

Two arm parallel group randomized controlled clinical trial. Online randomization program will be used for randomization.

##### Settings and conduct

This study will be a randomized and controlled clinical trial. Patients are selected from the intensive care unit (ICU) of Al-Zahra, Amin and Ayatollah Kashani hospitals in Isfahan. Adults with ventilator-associated pneumonia (VAP) are evaluated for inclusion in the study.

##### Participants/Inclusion and exclusion criteria

Age over 18 years  
Under mechanical ventilation (intubation) for more than 48 hours  
VAP diagnosis  
Growth of carbapenem-resistant *Acinetobacter baumannii* (Meropenem) in culturing lung secretions

##### Intervention groups

Experimental group: colistin (4.5 MU IV q12h) + levofloxacin (750 mg IV q24h)  
Control group: colistin (4.5 MU IV q12h) + meropenem (1 g IV q8h)

##### Main outcome variables

Clinical response (cure, improvement, or failure) CPIS score;

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20150721023282N17**

Registration date: **2021-05-12, 1400/02/22**

Registration timing: **prospective**

Last update: **2021-05-12, 1400/02/22**

Update count: **0**

##### Registration date

2021-05-12, 1400/02/22

##### Registrant information

##### Name

Rasool Soltani

##### Name of organization / entity

Isfahan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3792 7067

##### Email address

soltani@pharm.mui.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-06-22, 1400/04/01

##### Expected recruitment end date

2022-08-26, 1401/06/04

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the efficacy of colistin / levofloxacin in comparison with colistin / meropenem in the treatment of ventilator-associated pneumonia (VAP) induced by carbapenem-resistant *Acinetobacter baumannii*: a randomized, controlled clinical trial

**Public title**

Comparison of colistin / levofloxacin combination with colistin / meropenem combination in the treatment of ventilator-dependent upper respiratory tract (VAP) induced by *Acinetobacter*: a randomized controlled clinical trial

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age over 18 years Under mechanical ventilation (intubation) for more than 48 hours VAP diagnosis Growth of carbapenem (meropenem)-resistant *Acinetobacter baumannii* in the lung secretions culture

**Exclusion criteria:**

Pregnancy Lactation Sensitivity to meropenem, colistin, or levofloxacin Acute Respiratory Distress Syndrome Active pulmonary tuberculosis

**Age**

From **18 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **42**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Simple randomization was used for patients' allocation to the groups. For this, an online random number generator is used (available at: <https://www.random.org/sequences>) so that even and odd numbers will be considered for experimental and placebo groups, respectively, and each patient, after inclusion, will be assigned to the related group according to the determined sequence.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Isfahan University of Medical Sciences

**Street address**

Hezar-Jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**

خیابان هزار جریب

**Approval date**

2020-12-09, 1399/09/19

**Ethics committee reference number**

IR.MUI.RESEARCH.REC.1399.606

**Health conditions studied****1****Description of health condition studied**

Ventilator-induced pneumonia

**ICD-10 code**

J95.851

**ICD-10 code description**

Ventilator associated pneumonia

**Primary outcomes****1****Description**

Clinical Response (defined as cure or improvement or treatment failure)

**Timepoint**

End of intervention

**Method of measurement**

Clinical judgment by the observation of the patient

**Secondary outcomes****1****Description**

Clinical Pulmonary Infection Score (CPIS)

**Timepoint**

Before and after the intervention

**Method of measurement**

Questionnaire

**2****Description**

Mortality rate during the intervention

**Timepoint**

The end of intervention

**Method of measurement**

Counting

**Intervention groups**

**1**

**Description**

Experimental group: colistin (4.5 MU IV q12h) + levofloxacin (750 mg IV q24h), for 10 days

**Category**

Treatment - Drugs

**2**

**Description**

Control group: colistin (4.5 MU IV q12h) + meropenem (1 g IV q8h), for 10 days

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Al-Zahra Hospital; Amin Hospital of Isfahan; Kashani Hospital

**Full name of responsible person**

Dr. Rasool Soltani

**Street address**

Isfahan, Sefeh St., Al-Zahra Hospital

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174675731

**Phone**

+98 31 3620 2020

**Email**

soltani@pharm.mui.ac.ir

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Shaghayegh Haghjooy Javanmard

**Street address**

Hezar-Jerib Avenue, Isfahan University of Medical Sciences

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3668 0048

**Email**

reasearch@mui.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Esfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Rasool Soltani

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Faculty of Pharmacy, Hezar-Jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3792 7067

**Email**

soltani@pharm.mui.ac.ir

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Rasool Soltani

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Faculty of Pharmacy, Hezar-Jerib Ave.

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3792 7067

**Fax**

+98 31 3668 0011

**Email**

soltani@pharm.mui.ac.ir

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Phone**

+98 31 3792 7067

**Email**

soltani@pharm.mui.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Rasool Soltani

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Faculty of Pharmacy, Hezar-Jerib Ave.

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

En Confidentiality of patients data

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available